FDA
-
-
-
-
-
-
-
New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress
-
-
-
-
-
-
-
New data on lecanemab to be presented at CTAD conference
-
-
-
-
-
-
-
Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 - March 2026)
-
-
-
-
-
-
-
Leqembi® sales reaches €200 million - first sales milestone achieved
-
-
-
-
-
-
-
Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
-
-
-
-
-
-
-
Leqembi approved for the treatment of Alzheimer's disease in Israel
-
-
-
-
-
-
-
The European Medicines Agency's Scientific Advisory Group (SAG) to discuss the Marketing Authorisation Application for lecanemab: BioArctic
-
322,969 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

